Background: Diabetes is a common co-morbidity among hospital inpatients, particularly in medical wards. Diabetes is linked to increased length of stay and mortality in hospital inpatients, and hypoglycemia (hypo) is considered a contributory factor. We sought to determine the prevalence of diabetes in medical wards and the prevalence and patterns of hypo during their hospital stay.

Methods: A daily census on three medical wards (79 beds) was conducted over a 4 month period from June 2017 in a 3bed tertiary Sydney hospital. Charts and medications for inpatients with diabetes were audited each Friday using a questionnaire based on the UK National Diabetes Inpatient Audit. Patients admitted under the care of the diabetes team were excluded. Readmissions were counted as separate episodes.

Results: The mean prevalence of diabetes was 27%, of which 2.4% had T1DM, with 212 patient episodes audited in 196 patients (16 readmissions). Mean age (SD) was 71 years (11.2), 54% male. Only 5.6% had a diabetes related admission. Insulin use was 34% on admission but 52% during hospital stay. There were 74 events of hypo (<72 mg/dL) in 38 patients (18%), with 10 episodes of severe hypo (<54 mg/dL) in 9 patients (4.3%). Within the first week of admission, 50 of these hypo events occurred (8 severe) in 29 patients. Insulin was prescribed in 82% of the patients who had hypo (31/38), and 89% of those who had severe hypo (8/9), with only 50% of them admitted on insulin. A smaller number of hypo events occurred 8am-5pm compared to 5pm-8am (29 vs. 45), with no significant difference between days of the week.

Conclusion: Hypoglycemia is a major burden in patients with diabetes in hospital, particularly in the first week of admission, even when patients are not admitted due to diabetes related problems. Insulin use was the major risk factor and many patients had multiple hypo events. We recommend early involvement of the diabetes inpatient team as well as centralized point of care testing of glucose to allow early identification of patients at risk.


M.K. Piya: None. R. Zarora: None. T. Fletcher: None. D. Simmons: Speaker's Bureau; Self; Roche Diabetes Care Health and Digital Solutions, AstraZeneca, Novo Nordisk Inc., Medtronic.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at